International Psoriasis Council
The United States Food and Drug Administration (FDA) has approved deucravacitinib to treat psoriasis. Recently, 52-week efficacy and safety data
Real-world evidence studies become crucial to achieving the evidence needed in clinical practice. But how are data evaluated in the
Sleep disorders are frequently found in patients with psoriasis, but the specific factors have remained elusive and have never been
In personalized care for patients, psoriasis biomarkers will be highly relevant. At present, various centers have investigated biomarkers and their
The COVID-19 pandemic has been a significant concern, and vaccination has been crucial worldwide in its combat.
IPC Councilor, Carlo Pincelli, MD, shares his expert opinion on innovative research that connects insights into immunopathogenesis with genetics and
A research group led by Catherine Smith from St John’s Institute of Dermatology described humoral and cellular immunity.
The safety of treatment for immune-mediated diseases like psoriasis during the COVID-19 pandemic is a matter of concern. In an
In the April 2021 issue of the Lancet, four of our esteemed colleagues in the IPC published an updated and
Because of the growing body of evidence indicating sex differences in the clinical outcomes of coronavirus disease 2019 (COVID-19) infection,